Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rocket Doctor AIAIRDF -1.16%29 3-Year EBITDA Growth Rate is 32.60% as of Mar. 2026, which is 30% above its 10-year median of 25.10. GuruFocus rates AIRDF with a GF Score™ of 29/100. The stock has 7 warning signs investors should review. Among 527 Healthcare Providers & Services companies, Rocket Doctor AI ranks better than 78.94% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 32.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 30.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Rocket Doctor AI was 56.70% per year. The lowest was -79.20% per year. And the median was 25.10% per year.
Rocket Doctor AI (OTCPK:AIRDF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Rocket Doctor AI 3-Year EBITDA Growth Rate Related Terms
AIRDF vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Rocket Doctor AI's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rocket Doctor AI 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Rocket Doctor AI's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Rocket Doctor AI's 3-Year EBITDA Growth Rate falls into.
Rocket Doctor AI 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 32.60% mean?
Rocket Doctor AI (AIRDF) has a 3-Year EBITDA Growth Rate of 32.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rocket Doctor AI and its competitors. This is 30% above median its historical median of 25.10. According to the industry distribution chart, Rocket Doctor AI ranks #111 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 21.1%.
Is Rocket Doctor AI's 3-Year EBITDA Growth Rate too high?
Rocket Doctor AI's current 3-Year EBITDA Growth Rate of 32.60% is 30% above median its 10-year median of 25.10. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Rocket Doctor AI's value of 32.60% is 219.6% above this industry median. Based on the distribution chart, Rocket Doctor AI ranks #111 out of 527 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Rocket Doctor AI has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Doctor AI's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Rocket Doctor AI ranks #111 out of 527 companies for 3-Year EBITDA Growth Rate. This places Rocket Doctor AI in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.20. Rocket Doctor AI's value of 32.60% is 219.6% above this benchmark. While the company's 10-year median is 25.10 vs. the industry median of 10.20, Rocket Doctor AI has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rocket Doctor AI's current 3-Year EBITDA Growth Rate of 32.60% is 219.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rocket Doctor AI and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rocket Doctor AI's current 3-Year EBITDA Growth Rate is 32.60%, which is 30% above median its own 10-year median of 25.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Doctor AI stock overvalued right now?
Rocket Doctor AI (AIRDF) has a current 3-Year EBITDA Growth Rate of 32.60%. The current 3-Year EBITDA Growth Rate is 32.60%, which is 30% above median its 10-year median of 25.10 and 219.6% above the Healthcare Providers & Services industry median of 10.20. Rocket Doctor AI's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Rocket Doctor AI (AIRDF), the current 3-Year EBITDA Growth Rate is 32.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rocket Doctor AI Inc delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company's proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians world-wide. Alongside the GLM and its AI-powered digital health platform and marketplace. The group empowers over 300 MDs to provide care to more than 700,000 patients. Its proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices - improving efficiency, restoring autonomy to MDs, and expanding patient access to care.
29GF Score
Get the complete analysis for AIRDF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIRDF has been successfully added to your 
